Results 61 to 70 of about 418,673 (161)

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj, Marvin Fischer, Michael B. Davidson, Abdul M. Tarafder, Christopher J. Michaels, Rachel H. Tao, Alex Pashley, Jess Amis, Josefine Redig   +8 more
wiley   +1 more source

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A combination of drugs is required for treatment of obese subjects with diabetes, due to multiple pathogenic mechanisms implicated in the development of both diabetes and obesity. Objective.
Beljić-Živković Teodora, Marjanović-Petković Milica, Vuksanović Miljanka, Soldatović Ivan, Kanlić Dobrila, Topalov Drina   +5 more
doaj   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Dorsal Pancreatic Agenesis Associated With New‐Onset Diabetes Mellitus and Acute Pancreatitis in an 18‐Year‐Old Man: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Dorsal pancreatic agenesis (DPA) is a rare congenital disorder resulting from failure of development of the dorsal pancreatic bud. Complete DPA implies absence of the pancreatic neck, body, and tail and can be associated with both diabetes mellitus and pancreatitis. The patient was an 18‐year‐old man admitted with a history of epigastric pain,
Mugheesa Rab, Muhammad Hassaan Javaid, Rabia Narmeen Numani, Fozia Khanam, Muddassir Khalid, Fred Segawa   +5 more
wiley   +1 more source

When Current Severity Overrides Reassuring Findings: TG18‐Guided Biliary Drainage in ERCP‐Confirmed Purulent Cholangitis

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 42‐year‐old antibiotic‐naïve man with previous laparoscopic cholecystectomy and poorly controlled type 2 diabetes mellitus (HbA1c 9.7%) presented with Charcot's triad 7 days after a formally documented normal hepatobiliary evaluation (alanine aminotransferase [ALT] 22 U/L; total bilirubin 0.7 mg/dL [12 μmol/L]; common bile duct [CBD] ≤ 5 mm ...
Hatem Mousa Taha, Khaled Hatem Taha
wiley   +1 more source

Insulin Glargine and Risk of Cancer: A Meta-Analysis

The International Journal of Biological Markers, 2012
Aims Recently, more and more attention has been drawn on the long-term effects of insulin glargine. Here we strived to estimate the association of cancer occurrence with the use of insulin glargine.
Xinli Du, Rihua Zhang, Yi Xue, Dong Li, Jinmei Cai, Suming Zhou, Zhengkai Huang, Rongbin Yu, Yun Liu Phn   +8 more
doaj   +1 more source

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9607-9620, October 2026.
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Linong Ji, Jonas Dahl Andersen, Malik Benamar, Paola Ponzani, A. G. Unnikrishnan, Siri Vinther, Rosangela Rea   +6 more
wiley   +1 more source

rDNA insulin glargine U300 – a critical appraisal

, 2016
Fei Wang,1 Stefanie Zassman,1 Philip A Goldberg2 1Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, CT, USA; 2Department of Internal Medicine, Section of Endocrinology, Yale University School of Medicine, New Haven ...
Goldberg PA, Wang F, Zassman S
core  

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9091-9100, October 2026.
ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Saichun Zhang, Yunjuan Gu, Yu Cheng, Ying Hu, Bing Li, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Minlu Zhang, Yini Jiang, Qin Du, Lei Kang, Yiming Mu, Weijun Gu, Hongyu Kuang   +14 more
wiley   +1 more source

Insulin glargine use and breast cancer risk:Associations with cumulative exposure [PDF]

, 2016
Background: This study was aimed to assess the risk of breast cancer associated with exposure to insulin glargine in women with type 2 diabetes and evaluate whether the pattern of risk concurs with the hypothesized trend of an increase in risk with ...
Peeters, Paul J. H. L., Marie L. De Bruin (391653), van Staa, Tjeerd P.; id_orcid, Sub Pharmacoepidemiology, Hubert G. M. Leufkens (193774), Leufkens, Hubert G, Peeters, Paul J, van Staa, Tjeerd P., De Bruin, Marie L, Bazelier, Maroles T, Anssi Auvinen (24931), Pharmacoepidemiology and Clinical Pharmacology, Sub Gen. Pharmacoepi and Clinical Pharm, Marloes T. Bazelier (2697898), Peeters, Paul J H L, Auvinen, Anssi, Leufkens, Hubert G M, Sub Clinical Pharmacy, Pharmacoepi, Leufkens, Hubert G. M., Paul J. H. L. Peeters (2697895), de Vries, Frank; id_orcid, Tjeerd P. van Staa (193778), Bazelier, Marloes T, Frank de Vries (430757), De Bruin, Marie L., de Vries, Frank, van Staa, Tjeerd P, Bazelier, Marloes T.   +27 more
core   +2 more sources